Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
May 19, 2023 09:00 ET
|
Candel Therapeutics
Treatment with CAN-3110 in arm A showed encouraging median overall survival rate at 11.8 months after a single injection. These data are supported by independent cohort (arm B); median overall...
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
May 11, 2023 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and...
Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO
May 02, 2023 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies...
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer
April 17, 2023 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and...
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
March 30, 2023 08:00 ET
|
Candel Therapeutics
Expects to announce clinical trial data from multiple oncology programs in the second half of 2023Extends cash runway into second quarter of 2024 NEEDHAM, Mass., March 30, 2023 (GLOBE...
Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day
February 01, 2023 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that...
Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference
January 12, 2023 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that...
Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer
December 06, 2022 16:26 ET
|
Candel Therapeutics
Updated data from the phase 2 clinical trial of CAN-2409 in non-small cell lung cancer showing disease control rate of 77 percent in patients entering the study with progressive disease, translating...
Candel Therapeutics to Host Virtual R&D Day on December 6, 2022
November 29, 2022 08:00 ET
|
Candel Therapeutics
New clinical data to be presented from the Company’s phase 2 clinical trial of CAN-2409 in combination with anti-PD-1 agents in patients with late-stage non-small cell lung cancer.Recent clinical data...
Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting
November 18, 2022 08:00 ET
|
Candel Therapeutics
CAN-3110 designed to limit replication and promote anti-tumor response to tumor cells while protecting healthy tissueNo dose-limiting toxicities observed in 41 patients with recurrent high-grade...